Evidence map›Paper›PMID 39734690›Full record

ArticleThe Lancet regional health. Europe2025

HBV and HCV testing outcomes among marginalized communities in Italy, 2019-2024: a prospective study.

Monica Monti, Teresita Caruso, Alice Castellaccio, Irene De Giorgi, Gabriella Cavallini, Maria Laura Manca, Serena Lorini, Silvia Marri, Luisa Petraccia, Francesco Madia and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Monica MontiMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Teresita CarusoMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Alice CastellaccioSan Jacopo Hospital, Infectious Disease Unit, Pistoia, Italy.
Irene De GiorgiMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Gabriella CavalliniDepartment of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
Maria Laura MancaDepartment of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa and University Hospital of Pisa, Pisa, Italy.
Serena LoriniMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Silvia MarriDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology, University of Florence, Florence, Italy.
Luisa PetracciaPoison Control Center Unit, Department of Emergency, Anesthesia and Critical Care Medicine, Policlinico Umberto I Hospital - Sapienza, University of Rome, Rome, Italy.
Francesco MadiaMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Cristina StasiRegional Health Agency of Tuscany, Florence, Italy.
Laura CarraresiDepartment of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology, University of Florence, Florence, Italy.
Elisabetta LoreficeSan Giuseppe Hospital, Gastroenterology Unit, Empoli, Italy.
Sara Irene BonelliSan Jacopo Hospital, Infectious Disease Unit, Pistoia, Italy.
Alessandro NerliSanto Stefano Hospital, Infectious Disease Unit, Prato, Italy.
Mouheb M A MudalalMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Lorenzo MartiniMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Stefano GittoMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Eleonora CarradoriMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Adela XhekaMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Irene BendiniMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Samuele Lukolic'Department of Health Sciences, University of Florence, Florence, Italy.
Lorenzo LatellaDepartment of Health Sciences, University of Florence, Florence, Italy.
Donatella AquiliniSanto Stefano Hospital, Infectious Disease Unit, Prato, Italy.
Pierluigi BlancSan Jacopo Hospital, Infectious Disease Unit, Pistoia, Italy.
Anna Linda ZignegoMASVE Interdepartmental Hepatology Center, Department of Experimental and Clinical Medicine, University of Florence, Center for Research and Innovation CRIA-MASVE, Firenze, Italy.
Laura GragnaniDepartment of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The health of the marginalized populations is crucial for public health and inequalities. The World Health Organization (WHO) Global Hepatitis Report 2024 stated that over 304 million people were living with Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) infection in 2022. We performed HBV/HCV screenings among marginalized communities to reveal hidden infections and link-to-care positive participants. Methods: From January 2019 to May 2024, finger-prick tests were used to conduct on-site screenings at non-profit organizations in Tuscany, Italy. Positive participants were referred to the closest outpatient clinic. Findings: Eighty/1812 (4.4%) participants were Hepatitis B surface Antigen (HBsAg)+, mostly men ( Interpretation: We found higher HBV/HCV positivity compared to national prevalences. Participation and linkage to care were successful. The young mean age (33.6 yrs) of HBsAg + individuals, primarily from regions with low vaccinal adherence, indicated geographical origin as a key risk factor. HCV positivity was associated with extreme marginality. The results stress the need to implement marginalized groups screening to target HBV/HCV hidden infections, reducing disparities in healthcare and advancing towards the WHO 2030 elimination goal. Funding: Gilead Sciences; Fondazione Cassa di Risparmio di Pistoia e Pescia; Regione Toscana.

Indexed as

Healthcare disparitiesHepatitis B virusHepatitis C virusMarginalized populationsWorld Health Organization

Identifiers

PMID39734690
PMCPMC11681880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.